Elena Marquez Sells 4,291 Shares of Anterix (NASDAQ:ATEX) Stock

Anterix Inc. (NASDAQ:ATEXGet Free Report) CFO Elena Marquez sold 4,291 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $79.50, for a total transaction of $341,134.50. Following the transaction, the chief financial officer directly owned 18,387 shares in the company, valued at $1,461,766.50. This trade represents a 18.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Anterix Price Performance

Shares of ATEX opened at $74.53 on Friday. Anterix Inc. has a one year low of $17.58 and a one year high of $88.12. The company has a market cap of $1.40 billion, a PE ratio of 15.40 and a beta of 0.95. The stock has a 50-day moving average of $57.36 and a 200-day moving average of $39.26.

Hedge Funds Weigh In On Anterix

Several large investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC raised its stake in shares of Anterix by 63.7% in the first quarter. Parallel Advisors LLC now owns 933 shares of the company’s stock worth $36,000 after purchasing an additional 363 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Anterix by 0.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 138,677 shares of the company’s stock valued at $3,027,000 after buying an additional 599 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Anterix by 12.4% during the second quarter. Russell Investments Group Ltd. now owns 5,760 shares of the company’s stock worth $148,000 after buying an additional 637 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Anterix by 17.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,084 shares of the company’s stock valued at $182,000 after buying an additional 1,029 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Anterix by 299.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,645 shares of the company’s stock valued at $42,000 after acquiring an additional 1,233 shares in the last quarter. Institutional investors own 87.67% of the company’s stock.

Analysts Set New Price Targets

ATEX has been the subject of a number of research reports. B. Riley Financial cut Anterix from a “buy” rating to a “neutral” rating and raised their price objective for the company from $44.00 to $69.00 in a research note on Thursday, June 4th. Weiss Ratings raised Anterix from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Anterix has an average rating of “Hold” and an average target price of $59.50.

View Our Latest Report on ATEX

About Anterix

(Get Free Report)

Anterix, Inc is a specialized telecommunications company focused on delivering private broadband networks for utilities and other critical infrastructure industries. The company owns and operates dedicated 900 MHz spectrum that enables reliable, secure and high-performance wireless communications to support grid modernization, smart metering, distribution automation and other mission-critical applications. By leveraging this spectrum, Anterix helps electric, water and gas utilities deploy advanced communications capabilities to enhance operational efficiency and resiliency.

At the core of Anterix’s offering is its licensed 900 MHz spectrum, which provides superior propagation characteristics compared with unlicensed options and allows for cost-effective coverage over expansive service territories.

See Also

Insider Buying and Selling by Quarter for Anterix (NASDAQ:ATEX)

Receive News & Ratings for Anterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anterix and related companies with MarketBeat.com's FREE daily email newsletter.